Decreasing mortality with primary percutaneous coronary intervention in patients with acute myocardial infarction: The Mayo Clinic experience from 1991 through 1997

Mayo Clinic Proceedings

Volumn 75, Issue 10, 2000, Pages 994-1001

  Velianou, James L ^a,b   Wilson, Stephanie H ^a   Reeder, Guy S ^a   Caplice, Noel M ^a   Grill, Diane E ^a   Holmes, David R ^a   Bell, Malcolm R ^a  

^a MAYO CLINIC   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; REPERFUSION; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; ADJUVANT THERAPY; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; FOLLOW UP; HOSPITAL DISCHARGE; MIDDLE AGED; MORTALITY RATE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

EID: 0033800107     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.10.994     Document Type: Article

References (41)

1. Grines CL, Browne KR, Marco J, et al., Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N EnglJ Med. 1993;328:673-679.
2. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N EnglJ Med. 1993;328:680-684.
3. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ, Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993:328:685691.
4. Stone GW, Grines CL, Browne KF, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am Coll Cardiol. 1995:25:370-377.
5. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? a quantitative overview (meta-analysis) of the randomized clinical trials. Circulation. 1995; 91:476-485.
6. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review [published correction appears in JAMA. 1998;279:1876], JAMA. 1997:278:2093-2098.
7. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation. 1998:98:1802-1820.
8. Schomig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographie outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol. 1997:29:2834.
9. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol. 1998;31:1234-1239.
10. Stone GW, Brodie BR, Griffin JJ, et al. Clinical and angiographie follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation. 1999;99:1548-1554.
11. Lefkovits J, Ivanhoe RJ, Califf RM, et al., EPIC Investigators. Effects of platelet glycoprotein Ilb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 1996:77:1045-1051.
12. Azar RR, McKay RG, Thompson PD, et al. Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes. J Am Co/1 Cardiol. 1998;32: 1996-2002.
13. Brener SJ, Barr LA, Burchenal JE, et al., ReoPro and Primary PICA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein lib/ Ilia blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998:98:734-741.
14. van den Merkhof LF, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 1999:33:1528-1532.
15. National Heart, Lung, and Blood Institute Coronary Artery Surgery Study: a multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography. Circulation. 1981:63(6, pt 2):I1-I81.
16. Armitage P. Tests for linear trends in proportions and frequencies. Biometrie!,. 1955; 11:375-385.
17. Grines CL, Marsalese DL, Brodie B, et al., PAMI-II Investigators. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol. 1998;31:967-972.
18. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol. 1997:30:1729-1734.
19. Gold HK. Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observation in animals and humans. Circulation. 1997;95:1755-1759.
20. Antman EM, Giugliano RP, Gibson CM, et al., TIMI 14 Investigators. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation. 1999:99:2720-2732.
21. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein Ilb/IIIa with eptifibatide in patients with acute coronary syndromes. N EnglJ Med. 1998:339:436-443.
22. Platelet Receptor Inhibition in Ischémie Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein Ilb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Eng/ J Med. 1998:338:1488-1497.
23. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein Ilb/IIIa inhibitor). heparin, or both in unstable angina. Circulation. 1998:97:2386-2395.
24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
25. Schwanz L, Bourassa MG, Lespérance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988:318:17141719.
26. Schuhlen H, Hadamitzky M, Walter H, Ulm K, Schomig A. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation. 1997:95:2015-2021.
27. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.N EnglJ Med. 1996:334:1084-1089.
28. Lincoff AM, Topol EJ, Califf RM, et al., Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction trials). Am J Cordial. 1995:75:871-876.
29. Ross AM, Coyne KS, Moreyra E, et al., GUSTO-I Angiographie Investigators. Extended mortality benefit of early postinfarction reperfusion. Circulation. 1998:97:1549-1556.
30. Yusuf S, Peto R, Lewis J, Coilins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985:27:335-371.
31. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986:2:5766.
32. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995:345:669-685.
33. Gruppo Italiano per lo Studio della Sopravvivenza neH'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994:343:11151122.
34. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994:344:1383-1389.
35. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng/J Med. 1996:335:1001-1009.
36. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998:339: 1349-1357.
37. Yusuf S, Furberg CD. Effects of calcium channel blockers on survival after myocardial infarction. Cardiovasc Drugs Ther. 1987; 1:343-344.
38. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995:92:1326-1331.
39. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Do "America's Best Hospitals" perform better for acute myocardial infarction? N EnglJ Med. 1999:340:286-292.
40. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 1995:345:1616-1619.
41. Every NR, Parsons LS, Fihn SD, et al., MITI Investigators. Longterm outcome in acute myocardial infarction patients admitted to hospitals with and without on-site cardiac catheterization facilities. Circulation. 1997:96:1770-1775.